LOOP-ENERGY
6.10.2022 12:31:37 CEST | Business Wire | Press release
Loop Energy™ (TSX: LPEN), a developer and manufacturer of hydrogen fuel cells for commercial mobility, today announces two new customers, each developing medium-duty hydrogen-electric trucks.
Opex, a Colombian systems integrator of batteries and hydrogen fuel cells, and Avia Ingeniería, a Spanish electric powertrain provider and systems integrator, are both looking to trial hydrogen-electric vehicles in 2023.
Loop Energy enters the Pilot Phase of the Customer Adoption Cycle with both companies, expanding its presence in the dynamic European market and establishing its first relationship in the emerging South American market. The news comes after Loop Energy recently upgraded its purchase order guidance for the next 18 months.
Having supplied components and infrastructure for battery-electric vehicles for more than a decade, Opex identified fuel cells as a solution for commercial vehicles in Latin America two years ago. Starting with a prototype, Opex aims to develop a logistics truck using Loop Energy's S300 (30 kW) fuel cell as a range extender. Once built, the truck is expected to be trialed by a local fleet operator to evaluate how the technology can be deployed in larger truck applications.
Avia Ingeniería plans to also apply Loop Energy's 30 kW fuel cell as a range extender in a tractor-trailer transport truck. The truck is a part of the ShineFleet project, which features various Spanish technology and engineering companies including Técnicas Reunidas. The aim of the pilot is to demonstrate the feasibility of hydrogen technology and educate fleet operators on how to scale a fleet. A logistics fleet operator is expected to integrate the truck into its service routes once it is operational in 2023.
"We've seen positive growth when it comes to using fuel cells in medium-duty electric trucks," said Loop Energy Chief Commercial Officer, George Rubin. "Our team continues to identify manufacturers and fleet operators committed to the deployment of hydrogen-electric fleets worldwide. It is great to see Opex and Avia Ingeniería setting a positive example in their respective markets."
Climate Change mitigation, regulatory pressure and energy security concerns are compelling manufacturers and fleet operators to invest in and operate hydrogen-electric trucks instead of traditional diesel combustion engine vehicles. Benefits such as extended range, lighter weight and fast refuelling are key contributors to lower total cost of ownership, making fuel cell-powered vehicles an appealing zero-emissions solution.
About Opex S.A.S.
Opex S.A.S. is a colombian based company with 10 years of experience in the market. Among its main market activities are selling and renting of products as acid lead batteries, Li-Ion batteries, and Hydrogen fuel cells. The company also provides products as forklift trucks and batteries for warehouses, including installations and maintenance of the products. During the last two years, Opex has been involved in several research projects related to clean energies and hydrogen use. We have installed the first hydrogen refueling station in the entire South America region. To learn more visit: www.opex.com.co
About Avia Ingeniería
Avia is an independent company specializing in the design, manufacture of prototypes and small series of special vehicles. The philosophy of the company as engineering is to offer its capacity to develop advanced technology projects and to be present in research projects in the fields of new energies and materials. It offers its clients solutions from the simplest execution of manufacturing drawings to the most advanced integral projects, contributing, with its knowledge, technology and computer resources. Avia brings vast experience in the fields of aeronautics, automotive, agricultural equipment and public works.
About Loop Energy Inc.
Loop Energy is a leading designer and manufacturer of fuel cell systems targeted for the electrification of commercial vehicles, including light commercial vehicles, transit buses and medium and heavy-duty trucks. Loop's products feature the company's proprietary eFlow™ technology in the fuel cell stack's bipolar plates. eFlow™ is designed to enable commercial customers to achieve performance maximization and cost minimization. Loop works with OEMs and major vehicle sub-system suppliers to enable the production of hydrogen fuel cell electric vehicles. For more information about how Loop is driving towards a zero-emissions future, visit www.loopenergy.com.
Forward Looking Warning
This press release contains forward looking information within the meaning of applicable securities legislation, which reflect management’s current expectations and projections regarding future events. Particularly, statements regarding the Company’s or Customer’s expectations of future sales and deployment, performance, achievements, prospects or opportunities or the markets in which we operate is forward looking information, including without limitation statements regarding the trials and deployment of Opex’s and Avia’s hydrogen-electric truck, future purchase orders and projected benefits of fuel cell technology in commercial vehicles.
Forward looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control and could cause actual results and events to vary materially from those that are disclosed, or implied, by such forward looking information. Such risks and uncertainties include, but are not limited to, the ability to scale hydrogen technology into larger applications or fleets, if vehicle OEMs and fleet operators choose not to invest and operate zero-emissions vehicles over diesel vehicles, if the benefits of fuel cell technology in commercials does not contribute to lower total cost of ownership and the factors discussed under “Risk Factors” in the Company’s Annual Information Form dated March 23, 2022. Loop disclaims any obligation to update these forward looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221006005161/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
